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Background: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis.
The aim of this study was to assess SVR rate and its predictive factors in HCV advanced
fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the
adverse events related to treatment.
Methods: A multicentric, retrospective study was conducted at six university hospitals.
METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV
had their data analyzed. A stepwise logistic regression analysis was performed to identify
the variables independently related to SVR. Adverse events were recorded during treatment.
Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was
present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was
5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR
rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p=0.24). SVR
rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent
factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points.
Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver
cirrhosis.
Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed.
However, a very careful evaluation of cirrhotic patients must be performed before treatment
is indicated and careful monitoring is required during treatment.
© 2013 Published by Elsevier Editora Ltda.
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Introduction
Hepatitis C virus (HCV) infects more than 170 million peo-
ple worldwide, and is the leading cause of hepatocellular
carcinoma and liver transplantation in the western world.1
When cirrhosis is established, the risk of clinical decom-
pensation is high. Furthermore, tolerance and response to
antiviral treatment in advanced fibrosis is poor.2–4 Neverthe-
less, achievement of a sustained virological response (SVR) in
these patients reduces the incidence of hepatic decompensa-
tion as well as the development of hepatocellular carcinoma
and death.5–7 Recently, a meta-analysis showed that even
if SVR is not achieved, interferon therapy could be asso-
ciated with prevention of HCC development.7 Hence, HCV
infection eradication in this population might be stimu-
lated.
However, results on therapeutic efficacy trialswith patients
with advanced fibrosis are hetereogeneous, and many stud-
ies consist of sub-analyses from pivotal trials.8,9 Real life
studies in this population are scarce. In addition, data is
heterogeneous comprising different treatment schedules like
alpha interferon (IFN) or alpha Pegylated interferon (PEG-IFN)
either as monotherapy or associated to ribavirin (RBV).2,5,10,11
With the recent approval of the protease inhibitors for HCV
treatment new adverse events will occur and this might
be balanced in this specific population. However, in many
countries these drugs havenot yet been approved andpatients
with advanced fibrosis are still treated with the associa-
tion of PEG-IFN and RBV. Notwithstanding, the combination
of PEG-IFN and RBV will still be necessary for the treat-
ment with the current protease inhibitors. Thus, the aim
of this study was to assess the rate of SVR and its predic-
tive factors in an HCV infected population with advanced
fibrosis treated in real life conditions with full dose pegin-
terferon alfa 2a or alfa 2b plus bodyweight-adjusted dose of
ribavirin and to evaluate the adverse events related to treat-
ment.
Patients and methods
A multicentric, retrospective study was conducted in six
University Hospitals in Brazil. The Ethics Committee of the
University Hospital of Botucatu School of Medicine, São Paulo,
approved the study protocol. All patients’ data were codi-
fied to guarantee anonymity. At each participating center the
local principal investigator identified eligible patients based
on predefined criteria and data was entered on a database.
The inclusion criteria were as follows: naïve HCV-RNA pos-
itive patients with bridging fibrosis (METAVIR score F3) or
cirrhosis (METAVIR score F4) at liver biopsy. Patients who
had clinical or ultrasonographic evidence of cirrhosis were
considered as cirrhotics without liver biopsy and were also
allocated as F4. Cirrhotic patients were considered as decom-
pensated at baseline if they were presented with jaundice,
ascites, esophageal varices or hepatic encephalopathy. The
exclusion criteria were: HIV or HBV co-infection, hepatocel-
lular carcinoma at baseline and Child–Pugh score higher than
9.
Patients were treated with full dose PEG-IFN alpha-2a or
alpha-2b and ribavirin according to body weight. Patients with
<75kg received 1000mg/d of ribavirin and those whose weight
was ≥75kg were treated with 1250mg/d. Treatment was based
on the criteria established by the Brazilian Ministry of Health
for treatment of chronic HCV infection. Treatment would be
interrupted at week 12 if less than a 2-log drop from baseline
viral load was identified. In those with at least 2-log drop in
viral load at week 12, a new viral load was performed at week
24 and if the HCV-RNA was detectable, treatment was stopped
as well. All patients were treated for 48 weeks regardless of
genotype.
Data included in the analysis were as follows: gender, age,
weight at baseline, fibrosis level defined by METAVIR score,
viral genotype, HCV-RNA levels at baseline and at weeks 4,
12, 24, 48 and 72, ribavirin dose (mg/kg), and platelet count.
Laboratory baseline data included in the analysis were liver
enzymes (ALT, AST and GGT) and liver function tests (albu-
min, bilirubin and INR). Child–Pugh score was registered for F4
patients. Reasons of reduction of either peginterferon or RBV
and for early treatment discontinuation were also recorded.
Three modalities of treatment response were defined: non-
responders (detectable HCV-RNA w24 or w48 or absence of
a two log reduction in the viral load at week 12), relapsers
(HCV-RNA undetectable at the end of treatment but detectable
24 weeks after the end of treatment), and sustained virologi-
cal response (undetectable HCV-RNA at week 24 after the end
of treatment). An intent-to-treat analysis was carried out in
patients receiving at least one dose of medication and those
patients who did not complete the treatment regimen were
classified as non-responders.
Statistical analysis
Data was recorded and analyzed using SPSS 17.0, Chicago, IL,
USA. Nominal variables are presented in absolute and relative
frequencies. For continuous variables, descriptive statistics
are presented asmeanand standarddeviation,withminimum
and maximum values. The associations between selected fac-
tors and SVR were analyzed by using the chi-square and
Fisher’s exact tests when indicated. A stepwise logistic regres-
sion analysis was performed in order to identify the variables
independently related to SVR. Variables who presented a p-
value <0.20 at the univariate analysis were included in the
regression analysis. A significance level of 5% was adopted.
Results
Three hundred and eight patients were included (62% male,
mean age of 52±10 yrs, median body weight was 76±15kg).
Regarding genotype, 232 (75%) patientswere genotype 1 and 72
(23%) genotype 3. Twoadditional patientswere genotype 2 (1%)
and genotype was inconclusive in 2 others (1%). Patients with
genotype 2 and inconclusive genotypewere excluded from the
analysis. Stage 3 fibrosis was present in 121 (39%) and stage
4 (cirrhosis) in 187 (61%) patients. In patients with stage 4,
the median Child Pugh score was 5.5–9 Mean baseline HCV-
RNA was 5.55±0.94 log. Mean platelet count at baseline was
141.735±59.649/mL.
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Table 1 – Comparative analysis between F3 and F4 patients according to baseline and on-treatment variables (n=304).
Variable F3 (n=121) F4 (n=187) p-Value
Age (yrs±SD) 49±11 52±9 0.16
Gender (% male) 35 65 0.034
PEG-IFN alfa 2b (%) 39 60 0.85
Genotype 1 (%) 41 59 0.134
Abnormal GGT(%) 37 63 0.022
Platelet count (×103) 161 (35–203) 120 (37–135) <0.001
Ribavirin (mg/kg) 14.6±2.07 14.5±2.10 0.9
RVR (%) 45 55 0.135
EVR (%) 46 54 0.16
PEG-IFN dose reduction (%) 15 85 <0.001
Ribavirin dos reduction (%) 41 59 0.53
RR (%) 9 13 <0.001
NR (%) 45 62 <0.001
SVR (%) 59 31 <0.001
Death (n) 0 6 <0.001
Table 2 – Logistic regression analysis (n=304) – final
model.
Variable OR 95% CI
F3×F4 2.5 1.2–5.4
Genotype 3 vs. 1 5.3 2.3–12.0
RVR 4.3 2.0–9.1
Efficacy of treatment
The global SVR rate was 34%, 11% were relapsers and 55%
were nonresponders. SVR rates did not differ significantly
between patients treated with peginterferon alfa 2a or alfa 2b
(34%×32%, respectively; p=0.24). Genotype 1 patients had a
higher SVR if the ribavirin dose was not reduced (p=0.02). On
the other hand, in genotype 3 patients, SVR was higher for
those whose peginterferon dose was not reduced from base-
line (0.002).
In the comparison between genotype 1 and genotype 3
patients, the SVRwas 36% and 77% respectively (p<0.001). The
comparative analysis between F3 and F4 patients is shown in
Table 1. The SVR rates according to Child–Pugh score were
26% for Child A and 18% for Child B. On the multivariate
analysis that included all patients (Table 2), the variables inde-
pendently associated with SVR were genotype 3 (OR 7.6, CI
3.12/20), fibrosis stage 3 (OR3.43, CI 1.49/7.93) andundetectable
HCV-RNA at 4th week of treatment (OR 8.69, CI 3.53/21.27). In
the logistic regression analysis that included only F4 patients,
the independent factors related to SVR were genotype 3, RVR
and fewer Child Pugh score points. This is shown in Table 3.
Table 3 – Logistic regression analysis including only F4
patients and SVR: final model (n=187).
Variable OR 95% CI
Genotype 3 vs. 1 3.49 1.072–11.404
RVR Child 0.1232.028 0.031–0.486
1.164 – 3.532
OR – odds ratio; CI – confidence interval; RVR – rapid virological
response; Child – score Child Pugh.
The positive (PPV) and negative predictive values (NPV) of
SVR were calculated for each genotype according to the pres-
ence of RVR and EVR. The results are displayed in Table 4.
Adverse events and adherence to treatment
Treatment interruption occurred in 94 (31%) patients. Treat-
ment was suspended in 39 (13%) patients due to failure to
obtain a 2-log drop at week 12 (non-responder patients). Treat-
ment was stopped due to cirrhosis decompensation in 12
patients (4%) and to non-adherence in 15 patients (5%). Over-
all, deathoccurred in six (1.9%) patients, allwith liver cirrhosis.
Among them, two were Child Pugh A and four patients Child
Pugh B. The causes of death were sepsis in three patients,
meningitis in onepatient, liver decompensation in onepatient
with overt encephalopathy and upper gastrointestinal bleed-
ing in another patient.
Discussion
This study aimed at evaluating the SVR rate in patients with
advanced fibrosis and its tolerance to treatment. It included
a substantial number of patients with cirrhosis. The main
finding was a SVR rate of 34%, which is considered high for
advanced fibrosis patients taking into account that 61% were
cirrhotic. In the subgroup of cirrhotic patients, SVR rate was
25% including all genotypes and 18% when only genotype 1
is considered. It is a real life study that shows that treatment
should be encouraged in this group owing to the potential ben-
efits related to SVR in HCV patients with advanced fibrosis.
Twometa-analyses byZhang et al. andCammàet al. suggested
Table 4 – Positive and negative predictive factors for SVR
according to genotype and viral kinetics in patients with
advanced fibrosis (n=304).
Genotype With RVR With EVR
1 PPV (%) 47 62
NPV (%) 82 93
3 PPV (%) 82 68
NPV (%) 54 86
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that IFN therapy could efficiently reduce HCC development
in patients with HCV-related cirrhosis.12,13 Thus all efforts
should be made to treat this population. On the other hand we
showed that a careful approach is necessary regarding adverse
events mainly in cirrhotic patients.
Nowadays in many countries the standard of care treat-
ment for genotype 1 patients is the triple therapy with
protease inhibitors.14,15 However, in some countries in South
America and Europe this treatment is not yet available due
to many concerns, mainly economic issues. Patients with
advanced fibrosis might not wait too long to start treatment
owing to the risk of decompensation of liver disease, which is
around 2–6% a year.16 The protease inhibitors are very potent
and confer higher SVRwhen compared to treatmentwith PEG-
IFN and ribavirin.17–20 However, many adverse events have
been described and an ongoing study in cirrhotic patients
with protease inhibitors has demonstrated serious adverse
events including death. It is possible that some naïve cirrhotic
patients that were not able to finish therapy with protease
inhibitors due to adverse events could benefit from treatment
with PEG-IFN and ribavirin, albeit with smaller chance of SVR.
This should be encouraged mainly in those cirrhotic patients
with RVR. In the present study, RVR was an independent
variable related to SVR. This was previously demonstrated
and although cirrhotic patients rarely achieve RVR this has
a strong positive predictive value for SVR.21,22 Another point
that should be considered for naïve patients with advanced
fibrosis whose treatment interruption was related to adverse
events is the IL28B genotype. Although it was not evaluated in
this study, we could wonder whether CC genotype patients
might have attained SVR if treatment was not interrupted
early. Although it has been demonstrated in this study that
METAVIR F4 patients have a lower SVR rate when treated with
PEG-IFN and RBV, maybe this regimen might be tried in CC
naïve cirrhotic patients with side effects related to protease
inhibitors. These patients could notwait for a better treatment
due to their advanced disease.
In this real life studyadherence to treatmentwas good, only
5% were non-adherent and 4% of the cirrhotic patients had
treatment interrupted owing to cirrhosis decompensation. It
should be pointed out that six patients died. This is lower
than the 16% previously reported by Giannini et al. However,
their study included only cirrhotic patients.23 In the ongoing
study on cirrhotics and protease inhibitors the mortality was
high owing to adverse events, mainly sepsis. It is well known
that cirrhosis is a risk factor for infection owing to decreased
opsonization capacity amongother related factors.24 Thisway,
although treatment with PEG-RBV or triple therapy should be
encouraged, these patients must have a very close follow-up
in order to avoid severe complications that might be more fre-
quent and more intense in this population when comparing
to non-cirrhotic patients.
In genotype 2 and 3 Hepatitis C patients, PEG-IFN and riba-
virin are still the mainstay of therapy. In the present study,
genotype 3 patients comprised 24% of the total sample and
genotype 2 were not included in the analysis owing to the
small number of genotype 2 patients. The SVR rate among
genotype 3 F3 patients was 77% and 46% in the cirrhotic group.
In genotype3patients, viral kinetics showeda remarkable role.
Achievement of RVR had a high positive predictive value for
SVR (82%) in genotype 3, much higher than the positive pre-
dictive value of RVR for genotype 1 which was 47%. Thus, if
available, an HCV-RNA should also be performed at week 4 of
treatment in genotype 3 patients.
There is no question that F3 patients with advanced fibro-
sis should always be put on therapy even before pangenotype
therapy is available for this group. In this study, genotype 1
patients treated with PEG-RBV had a 38% SVR while genotype
3 patients achieved 77% SVR. Even if these patients do not
achieve SVR the benefit of having been treated with PEG-RBV
and thus getting to know their viral kinetics profile will prob-
ably help to estimate their chance for SVR in a future triple
therapy based regimen.18,19
RBV dose was closely related to SVR in genotype 1 and PEG-
IFN in genotype 3. Ribavirin dose has already been reported to
be related to higher SVR rates.24 In the present study, themean
dose of RBV was 14.5mg/kg overall, and no difference was
observedbetween thedifferent genotypes. RBVdose reduction
was more frequent in cirrhotic patients with either genotype.
In the present study, the rate of treatment interruption
was similar to other studies. None of the decompensated cir-
rhotic patients obtained SVR. In addition, this subgroup had
more adverse events as well as treatment interruption when
compared to Child Pugh A cirrhotic patients included in this
study. Previous studies showed that treatment discontinua-
tion is higher among decompensated cirrhotic patients but
these studies alsodiscuss the importanceof trying to eradicate
HCV in this difficult to treat population.23 Treating this popu-
lation with protease inhibitors may be even more difficult. So
far, protease inhibitors are not indicated to decompensated
cirrhotic patients. Death rate was higher in the present study
and all deaths occurred in cirrhotic patients mainly in those
with a Child Pugh score B. Septicemia was the most frequent
etiology among those patients who died and this has already
been shown in another real life study with triple therapy.24
Thus, all efforts must be done in order to diagnose and treat
cirrhotic patients while still at Child Pugh A stage. The deci-
sion to treat a cirrhotic Child B patient should be made on an
individual basis, optimizing interferon dose when necessary
in case of adverse events. Furthermore, these patients can be
treated once they are at a liver transplant center.
In conclusion, patients with advanced fibrosis are very
difficult to treat mainly if they already have liver cirrhosis.
Although treatment may be the only chance to eradicate HCV
infection in these patients and thus prevent further disease
progression and decompensation it may also cause severe
adverse events anddeath.Avery careful evaluationof cirrhotic
patients must be performed before treatment is indicated
and careful monitoring of viral kinetics and adverse events
is required during treatment.
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